книга / 2016_Kaplan_USMLE_Step_1_Lecture_Notes_Pharmacology
.pdf
Steroid Hormones |
2 |
Learning Objectives
Describe clinical situations requiring the use of adrenal steroids, estrogens, and progestin
Solve problems concerning oral contraceptives
List the common complications of steroid hormone use
ADRENAL STEROIDS
λNonendocrine uses: For use in inflammatory disorders (and accompanying adverse effects), see Section VI, Drugs for Inflammatory and Related Disorders.
λEndocrine uses of glucocorticoids (e.g., prednisone, dexamethasone, hydrocortisone) and the mineralocorticoid (fludrocortisone) include:
–Addison disease replacement therapy
–Adrenal insufficiency states (infection, shock, trauma) supplementation
–Premature delivery to prevent respiratory distress syndrome supplementation
–Adrenal hyperplasia feedback inhibition of ACTH
λAdrenal steroid antagonists:
–Spironolactone
–Blocks aldosterone and androgen receptors (see Section III, Cardiac and Renal Pharmacology)
λMifepristone:
–Blocks glucocorticoid and progestin receptors
λSynthesis inhibitors:
–Metyrapone (blocks 11-hydroxylation)
–Ketoconazole
ESTROGENS
λPharmacology: Estradiol is the major natural estrogen. Rationale for synthetics is to ↑ oral bioavailability, ↑ half-life, and ↑ feedback inhibition of FSH and LH.
λDrugs:
–Conjugated equine estrogens (Premarin)—natural
–Ethinyl estradiol and mestranol—steroidal
279
Section VIII λ Endocrine Pharmacology
λClinical uses:
–Female hypogonadism
–Hormone replacement therapy (HRT) in menopause →↓ bone resorption (↓ PTH)
–Contraception—feedback ↓ of gonadotropins
–Dysmenorrhea
–Uterine bleeding
–Acne
–Prostate cancer (palliative)
λSide effects:
–General
ºNausea
ºBreast tenderness
ºEndometrial hyperplasia
º↑ gallbladder disease, cholestasis
ºMigraine
ºBloating
–↑ blood coagulation via ↓ antithrombin III and ↑ factors II, VII, IX, and X (only at high dose)
–Cancer risk
º↑ endometrial cancer (unless progestins are added)
º↑ breast cancer—questionable, but caution if other risk factors are present
ºDES given during breast feeding →↑ vaginal adenocarcinoma cancer in offspring
λOther drugs:
–Anastrozole
ºMode of action: aromatase inhibitor →↓ estrogen synthesis
ºUse: estrogen-dependent, postmenopausal breast cancer
|
|
Aromatase |
|
|
|
|
|
||
Androstenedione |
|
Estrone |
|
|
Estradiol |
||||
|
|
|
|
|
|
|
|||
(adrenal cortex) |
|
|
– |
|
(adipose) |
|
|
||
|
|
|
|
|
|
||||
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
Anastrozole
Figure VIII-2-1. Mechanism of Action of Anastrozole
–Clomiphene (fertility pill)
ºMode of action: ↓ feedback inhibition →↑ FSH and LH →↑ ovulation → pregnancy
ºUse: fertility drug
ºAdverse effect: ↑ multiple births
280
Chapter 2 λ Steroid Hormones
λSelective estrogen-receptor modulators (SERMs):
–Tamoxifen
ºVariable actions depending on “target” tissue
ºE-receptor agonist (bone), antagonist (breast), and partial agonist (endometrium)
ºPossible ↑ risk of endometrial cancer
ºUsed in estrogen-dependent breast cancer and for prophylaxis in highrisk patients
–Raloxifene
ºE-receptor agonist (bone), antagonist breast and uterus
ºWhen used in menopause, there is no ↑ cancer risk
ºUse: prophylaxis of postmenopausal osteoporosis, breast cancer
Table VIII-2-1. Comparison of Tamoxifen and Raloxifene in Various Tissues
Drug |
|
Bone |
|
Breast |
|
Endometrium |
Tamoxifen |
Agonist |
Antagonist |
Agonist |
|||
Raloxifene |
Agonist |
Antagonist |
Antagonist |
|||
PROGESTIN
λPharmacology: Progesterone is the major natural progestin. Rationale for synthetics is ↑ oral bioavailability and ↑ feedback inhibition of gonadotropins, especially luteinizing hormone (LH).
λDrugs:
–Medroxyprogesterone
–Norethindrone
–Desogestrel is a synthetic progestin devoid of androgenic and antiestrogenic activities, common to other derivatives
λClinical uses:
–Contraception (oral with estrogens)—depot contraception (medroxyprogesterone IM every 3 months)
–Hormone replacement therapy (HRT)—with estrogens to ↓ endometrial cancer
λSide effects:
–↓ HDL and ↑ LDL
–Glucose intolerance
–Breakthrough bleeding
–Androgenic (hirsutism and acne)
–Antiestrogenic (block lipid changes)
–Weight gain
–Depression
λAntagonist: mifepristone—abortifacient (use with prostaglandins [PGs])
281
Section VIII λ Endocrine Pharmacology
ORAL CONTRACEPTIVES
λPharmacology:
–Combinations of estrogens (ethinyl estradiol, mestranol) with progestins (norgestrel, norethindrone) in varied dose, with mono-, bi-, and triphasic variants
–Suppress gonadotropins, especially midcycle LH surge
λSide effects:
–Side effects are those of estrogens and progestins, as seen previously
λInteractions: ↓ contraceptive effectiveness when used with antimicrobials and enzyme inducers
λBenefits:
–↓ risk of endometrial and ovarian cancer
–↓ dysmenorrhea
–↓ endometriosis
–↓ pelvic inflammatory disease (PID)
–↓ osteoporosis
ANDROGENS
λPharmacology: include methyltestosterone and 17-alkyl derivatives with increased anabolic actions, e.g., oxandrolone, nandrolone
λUses:
–Male hypogonadism and for anabolic actions →↑ muscle mass, ↑ RBCs, ↓ nitrogen excretion
–Illicit use in athletics
λSide effects:
–Excessive masculinization
–Premature closure of epiphysis
–Cholestatic jaundice
–Aggression
–Dependence
λAntagonists:
–Flutamide: androgen receptor blocker—used for androgen-receptor– positive prostate cancer
–Leuprolide: GnRH analog—repository form used for androgen-receptor– positive prostate cancer
–Finasteride
º5-Alpha reductase inhibitor, preventing conversion of testosterone to dihydrotestosterone (DHT)
ºDHT is responsible for hair loss and prostate enlargement
ºUses: BPH, male pattern baldness
ºCaution: teratogenicity
282
Chapter 2 λ Steroid Hormones
|
5α-Reductase |
|
|
|
|
|
Hair loss |
|
|
|
|
|
|
||||
Testosterone |
|
DHT |
|
|
|
|
||
|
|
|
|
|
|
|||
|
|
|
|
|
|
Prostate |
||
|
|
|
|
|
|
|
|
|
|
|
– |
|
|
|
|
|
growth |
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
Finasteride
Figure VIII-2-2. Mechanism of Action of Finasteride
Chapter Summary
Adrenal Steroids
λThe nonendocrine uses in inflammatory disorders were discussed in the previous chapter.
λThe glucocorticoids are used to treat Addison disease and adrenal insufficiency states, as a supplement in infantile respiratory distress syndrome, and in adrenal hyperplasia.
Estrogens
λSynthetic estrogens are used to increase the oral bioavailability and half-life relative to that obtained with estradiol and to induce feedback inhibition of FSH and LH.
λThe uses and adverse affects of estrogens are listed.
λThe clinical uses of anastrozole (decreases estrogen synthesis), danazol (decreases ovarian steroid synthesis), clomiphene (decreases feedback inhibition), and the selective estrogen-receptor modulators tamoxifen and raloxifene are considered.
Progestin
λSynthetic progestins are used to increase oral bioavailability and half-life relative to progesterone and to induce feedback inhibition of gonadotropins, especially LH.
λThe progestin-like drugs, their use in contraception and in hormonal replacement therapy, and their adverse effects are considered.
λMifepristone is an antagonist used with PG as an abortifacient.
λThe pharmacology of oral contraceptives and their adverse effects, drug interactions, and benefits are pointed out.
Androgens
λClinically useful androgen analogs include methyltestosterone and 17-alkyl derivatives. Their clinical and illicit uses and side effects are presented.
λClinically useful drug antagonists are flutamide (an androgen-receptor blocker used to treat prostate cancer), leuprolide (a GnRH analog used to treat prostate cancer), and finasteride (a 5-α-reductase inhibitor used to treat benign prostatic hyperplasia and male pattern baldness).
283
Antithyroid Agents |
3 |
Learning Objectives
Describe the short-term effect of iodine on the thyroid and the most commonly used thioamides
Table VIII-3-1. The Synthesis of Thyroid Hormone and Action and Effects of Antithyroid Agents
Thyroid Hormone Synthesis |
|
Effects of Antithyroid Agents |
|
1. Active accumulation of iodide into gland |
|
Basis for selective cell destruction by 131I |
|
2. |
Oxidation of iodide to iodine by peroxidase |
|
Inhibited by thioamides |
3. |
Iodination of tyrosyl residues (organification) on thyroglobulin to |
|
Inhibited by thioamides |
|
form MIT and DIT |
|
|
4. |
Coupling of MIT and DIT to form T3 and T4 |
|
Inhibited by thioamides |
5. |
Proteolytic release of T3 and T4 from thyroglobulin |
|
Inhibited by high doses of iodide* |
6. Conversion of T4 to T3 via 5´ deiodinase in peripheral tissues |
|
Inhibited by propranolol* and propylthiouracil* |
|
Definition of abbreviations: MIT, monoiodotyrosine; DIT, diiodotyrosine; T3, triiodothyronine; T4, thyroxine. *Thyroid storm management may include the use of any or all of these agents.
Iodide |
2 |
|
Iodine |
3 MIT |
4 |
T3 |
T4 - TG |
|
|
|
|
DIT |
|
||||
Thyroid |
|
|
|
|
|
|||
peroxidase |
|
|
|
|
|
|||
|
TG |
|
1 |
5 |
TG |
|
|
Iodide |
T3 T4 |
6 T3 |
Figure VIII-3-1. Thyroid Hormone Synthesis
285
Section VIII λ Endocrine Pharmacology
λThioamides: propylthiouracil and methimazole
–Use: uncomplicated hyperthyroid conditions; slow in onset
–High-dose propylthiouracil inhibits 5′ deiodinase
–Common maculopapular rash
–Both drugs cross the placental barrier, but propylthiouracil is safer in pregnancy because it is extensively protein bound
λIodide
–Potassium iodide plus iodine (Lugol’s solution) possible use in thyrotoxicosis: used preoperatively →↓ gland size, fragility, and vascularity
–No long-term use because thyroid gland “escapes” from effects after 10 to 14 days
λI131: most commonly used drug for hyperthyroidism
Chapter Summary
λThe steps in thyroid hormone synthesis and the antithyroid agents’ effects upon them are summarized in Table VIII-3-1. The clinical uses and their potential complications are presented in greater detail for the thioamides (propylthiouracil and methimazole) and iodine.
286
